Endo and Allergan settle opioid case ahead of trial
Posted: 3 September 2019 | Victoria Rees (European Pharmaceutical Review) | No comments yet
The two pharma companies have agreed to pay $15 million to certain Ohio counties before an opioid abuse trial to be held in October.
Endo Pharmaceuticals and Allergan have announced settlements in a Cleveland federal court ahead of trials over the opioid abuse cases to be held in October. The two Cuyahoga and Summit counties of Ohio will be paid $10 million by Endo and $5 million from Allergan.
The payment will remove the pharmaceutical companies from the opioid defendant list. The companies deny wrongdoing, saying they complied with their legal obligations and did not cause the epidemic.
The multidistrict litigation is scheduled to start next month and represents nearly 2,000 different lawsuits under a single trial. The case is expected to span over seven weeks.
Endo’s chief legal officer, Matthew Maletta, called the settlement a “favourable outcome”.
Other companies to still face charges include Purdue Pharma, Teva Pharmaceuticals and Johnson & Johnson.
Related topics
Related organisations
Allergan, Endo Pharmaceuticals, Johnson & Johnson, Purdue Pharma, Teva Pharmaceuticals
